摘要
目的:探讨不同链长神经酰胺(Cer)与A型主动脉夹层患者术后发生心力衰竭的关系。方法:回顾性收集2018年9月至2018年12月,就诊于首都医科大学附属北京安贞医院A型主动脉夹层住院并进行手术治疗患者共31例。在Thermo TSQ QUANTIVA质谱仪上进行定量检测血浆神经酰胺水平,通过医院病例系统及电话联系患者确定术后30d是否发生心力衰竭,分为发生心力衰竭组9例和未发生心力衰竭组22例,分析两组患者之间不同链长神经酰胺的差异,使用SPSS、Stata软件进行数据分析。结果:结果表明,两组比较Cer(d18:1/16:0)(P=0.012)、Cer(d18:1/18:0)(P=0.008)及Cer(d18:1/18:0)/Cer(d18:1/20:0)(P=0.002)在两组间均存在差异。在校正混杂因素后,Cer(d18:1/18:0)/Cer(d18:1/20:0)水平与A型主动脉夹层术后30d内发生心力衰竭进行Logistic回归,(优势比为1.933, 95%CI:1.027~3.640, P=0.041)。结论:不同链长神经酰胺与A型主动脉夹层患者术后发生心力衰竭有关。
Objective: Toexplore the relationship between different chain length ceramides and heart failure in patients with type A aortic dissection. Methods: a total of 31 patients with type A aortic dissection hospitalized and operated in Beijing Anzhen Hospital Affiliated to Capital Medical University from September 2018 to December 2018 were collected retrospectively, The plasma ceramide level was quantitatively detected by thermo TSQ quantiva mass spectrometer. Patients were contacted by the hospital HIS system and telephone to determine whether heart failure occurred 30 days after operation. The patients were divided into heart failure group(n=9) and without heart failure group(n=22). The differences of ceramide with different chain length between the two groups were analyzed, and the data were analyzed by SPSS and Stata software.Results: The resμLts showed that there were significant differences in Cer(d18:1/16:0)(P=0.012),Cer(d18:1/18:0)(P=0.008) and Cers(d18:1/18:0)/Cer(d18:1/20:0)(P=0.002) between the two groups. Use logistic regression, after adjusting for confounding factors, the odds ratio is 1.933.(95% CI:1.027–3.640,P=0.041). Conclusions: Ceramides of different chain lengths are associated with postoperative heart failure in patients with type A aortic dissection.
作者
王雪
姜文溪
任璐
王绿娅
王媛
杜杰
WANG Xue;JIANG Wenxi;REN Lu;WANG Lvya;WANG Yuan;DU Jie(Beijing Anzhen Hospital,Capital Medical University,Beijing Institute of Heart,Lung and Blood Vessel Diseases,The Key Laboratory of Remodeling Related Cardiovascular Disease,Beijing Collaborative Innovation Center for Cardiovascular Disorders,Beijing 100029,China)
出处
《心肺血管病杂志》
CAS
2022年第6期621-624,共4页
Journal of Cardiovascular and Pulmonary Diseases
基金
国家重点研发计划(2017YFC0908400)
国家自然科学基金(81870341)。